Modulating fibrinolytic activity—particularly through inhibition of PAI-1, α2AP, or uPAR signaling—holds promise as a novel therapeutic approach to reduce the vascular burden associated with T1D. Here, SERPINF2 is linked to type 1 diabetes mellitus.